HF 2508

Conference Committee Report - 87th Legislature (2011 - 2012) Posted on 04/19/2012 10:23am

1.1CONFERENCE COMMITTEE REPORT ON H. F. No. 2508

1.2A bill for an act

1.3relating to public safety; aligning state-controlled substance schedules with
1.4federal controlled substance schedules; modifying the authority of the Board of
1.5Pharmacy to regulate controlled substances; providing for penalties;amending
1.6Minnesota Statutes 2010, section 152.02, as amended; Minnesota Statutes 2011
1.7Supplement, section 152.027, subdivision 6.
1.8April 17, 2012
1.9The Honorable Kurt Zellers
1.10Speaker of the House of Representatives
1.11The Honorable Michelle L. Fischbach
1.12President of the Senate
1.13We, the undersigned conferees for H. F. No. 2508 report that we have agreed upon
1.14the items in dispute and recommend as follows:
1.15That the Senate recede from its amendments and that H. F. No. 2508 be further
1.16amended as follows:
1.17Delete everything after the enacting clause and insert:

1.18    "Section 1. Minnesota Statutes 2010, section 152.02, as amended by Laws 2011,
1.19chapter 53, sections 4 and 5, is amended to read:
1.20152.02 SCHEDULES OF CONTROLLED SUBSTANCES;
1.21ADMINISTRATION OF CHAPTER.
1.22    Subdivision 1. Five schedules. There are established five schedules of controlled
1.23substances, to be known as Schedules I, II, III, IV, and V. Such The schedules shall
1.24initially consist of the substances listed in this section by whatever official name, common
1.25or usual name, chemical name, or trade name designated.
1.26    Subd. 2. Schedule I. The following items are listed in Schedule I: (a) Schedule I
1.27consists of the substances listed in this subdivision.
1.28(1) (b) Opiates. Unless specifically excepted or unless listed in another schedule,
1.29any of the following substances, including their analogs, isomers, esters, ethers, salts, and
1.30salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence
2.1of the analogs, isomers, esters, ethers and salts is possible within the specific chemical
2.2designation:
2.3(1) acetylmethadol;
2.4(2) allylprodine;
2.5(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
2.6levomethadyl acetate);
2.7(4) alphameprodine;
2.8(5) alphamethadol;
2.9(6) alpha-methylfentanyl benzethidine;
2.10(7) betacetylmethadol;
2.11(8) betameprodine;
2.12(9) betamethadol;
2.13(10) betaprodine;
2.14(11) clonitazene;
2.15(12) dextromoramide; dextrorphan;
2.16(13) diampromide;
2.17(14) diethyliambutene;
2.18(15) difenoxin;
2.19(16) dimenoxadol;
2.20(17) dimepheptanol;
2.21(18) dimethyliambutene;
2.22(19) dioxaphetyl butyrate;
2.23(20) dipipanone;
2.24(21) ethylmethylthiambutene;
2.25(22) etonitazene;
2.26(23) etoxeridine;
2.27(24) furethidine;
2.28(25) hydroxypethidine;
2.29(26) ketobemidone;
2.30(27) levomoramide;
2.31(28) levophenacylmorphan;
2.32(29) 3-methylfentanyl;
2.33(30) acetyl-alpha-methylfentanyl;
2.34(31) alpha-methylthiofentanyl;
2.35(32) benzylfentanyl beta-hydroxyfentanyl;
2.36(33) beta-hydroxy-3-methylfentanyl;
3.1(34) 3-methylthiofentanyl;
3.2(35) thenylfentanyl;
3.3(36) thiofentanyl;
3.4(37) para-fluorofentanyl;
3.5(38) morpheridine;
3.6(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.7(40) noracymethadol;
3.8(41) norlevorphanol;
3.9(42) normethadone;
3.10(43) norpipanone;
3.11(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.12(45) phenadoxone;
3.13(46) phenampromide;
3.14(47) phenomorphan;
3.15(48) phenoperidine;
3.16(49) piritramide;
3.17(50) proheptazine;
3.18(51) properidine;
3.19(52) propiram;
3.20(53) racemoramide;
3.21(54) tilidine;
3.22(55) trimeperidine.
3.23(2) (c) Opium derivatives. Any of the following opium derivatives substances,
3.24their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless
3.25listed in another schedule, whenever the existence of the analogs, salts, isomers and salts
3.26of isomers is possible within the specific chemical designation:
3.27(1) acetorphine;
3.28(2) acetyldihydrocodeine; acetylcodone;
3.29(3) benzylmorphine;
3.30(4) codeine methylbromide;
3.31(5) codeine-n-oxide;
3.32(6) cyprenorphine;
3.33(7) desomorphine;
3.34(8) dihydromorphine;
3.35(9) drotebanol;
3.36(10) etorphine;
4.1(11) heroin;
4.2(12) hydromorphinol;
4.3(13) methyldesorphine; methylhydromorphine
4.4(14) methyldihydromorphine;
4.5(15) morphine methylbromide;
4.6(16) morphine methylsulfonate;
4.7(17) morphine-n-oxide;
4.8(18) myrophine;
4.9(19) nicocodeine;
4.10(20) nicomorphine;
4.11(21) normorphine;
4.12(22) pholcodine;
4.13(23) thebacon.
4.14(3) (d) Hallucinogens. Any material, compound, mixture or preparation which
4.15contains any quantity of the following hallucinogenic substances, their analogs, salts,
4.16isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically
4.17excepted or unless listed in another schedule, whenever the existence of the analogs, salts,
4.18isomers, and salts of isomers is possible:
4.193,4-methylenedioxy amphetamine (1) methylenedioxy amphetamine;
4.203,4-methylenedioxymethamphetamine (2) methylenedioxymethamphetamine;
4.21(3) methylenedioxy-N-ethylamphetamine (MDEA);
4.22(4) n-hydroxy-methylenedioxyamphetamine;
4.23(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
4.24(6) 2,5-dimethoxyamphetamine (2,5-DMA);
4.25(7) 4-methoxyamphetamine;
4.26(8) 5-methoxy-3, 4-methylenedioxy amphetamine;
4.27(9) alpha-ethyltryptamine;
4.28(10) bufotenine;
4.29(11) diethyltryptamine;
4.30(12) dimethyltryptamine;
4.31(13) 3,4,5-trimethoxy amphetamine;
4.32(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
4.33(15) ibogaine;
4.34(16) lysergic acid diethylamide (LSD); marijuana;
4.35(17) mescaline;
4.36(18) parahexyl;
5.1(19) N-ethyl-3-piperidyl benzilate;
5.2(20) N-methyl-3-piperidyl benzilate;
5.3(21) psilocybin;
5.4(22) psilocyn;
5.5Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidine (23) tenocyclidine
5.6(TPCP or TCP);
5.7(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
5.8(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
5.9(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
5.10(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
5.11(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
5.12(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
5.13(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
5.14(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
5.15(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD);
5.162,5-dimethoxy-4-ethylphenethylamine, also known as (33)
5.174-ethyl-2,5-dimethoxyphenethylamine (2C-E);
5.182,5-dimethoxy-4-iodophenethylamine, also known as (34)
5.194-iodo-2,5-dimethoxyphenethylamine (2C-I);
5.20(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.21(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.22(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.23(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
5.24(2-CB-FLY);
5.25(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.26(40) alpha-methyltryptamine (AMT);
5.27(41) N,N-diisopropyltryptamine (DiPT);
5.28(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.29(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.30(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.31(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.32(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
5.33(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
5.34(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
5.35(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
5.36(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
6.1(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
6.2(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
6.3(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
6.4(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
6.5(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
6.6(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
6.7(57) methoxetamine (MXE);
6.8(58) 5-iodo-2-aminoindane (5-IAI);
6.9(59) 5,6-methylenedioxy-2-aminoindane (MDAI).
6.10(4) (e) Peyote, providing. All parts of the plant presently classified botanically as
6.11Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract
6.12from any part of the plant, and every compound, manufacture, salts, derivative, mixture,
6.13or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled
6.14substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious
6.15ceremonies of the American Indian Church, and members of the American Indian Church
6.16are exempt from registration. Any person who manufactures peyote for or distributes
6.17peyote to the American Indian Church, however, is required to obtain federal registration
6.18annually and to comply with all other requirements of law.
6.19(5) (f) Central nervous system depressants. Unless specifically excepted or unless
6.20listed in another schedule, any material compound, mixture, or preparation which contains
6.21any quantity of the following substances having a depressant effect on the central nervous
6.22system, including its, their analogs, salts, isomers, and salts of isomers whenever the
6.23existence of the analogs, salts, isomers, and salts of isomers is possible within the specific
6.24chemical designation:
6.25(1) mecloqualone;
6.26(2) methaqualone;
6.27(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
6.28(4) flunitrazepam.
6.29(6) (g) Stimulants. Unless specifically excepted or unless listed in another schedule,
6.30any material compound, mixture, or preparation which contains any quantity of the
6.31following substances having a stimulant effect on the central nervous system, including its,
6.32their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs,
6.33salts, isomers, and salts of isomers is possible within the specific chemical designation:
6.34    (1) aminorex;
6.35(2) cathinone;
6.36(3) fenethylline;
7.1    (4) methcathinone;
7.2(5) methylaminorex;
7.3(6) N,N-dimethylamphetamine;
7.4(7) N-benzylpiperazine (BZP);
7.54-methylmethcathinone (8) methylmethcathinone (mephedrone);
7.6(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
7.74-methoxymethcathinone (10) methoxymethcathinone (methedrone);
7.83,4 - methylenedioxypyrovalerone (11) methylenedioxypyrovalerone (MDPV);
7.9(12) fluoromethcathinone;
7.10(13) methylethcathinone (MEC);
7.11(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
7.12(15) dimethylmethcathinone (DMMC);
7.13(16) fluoroamphetamine;
7.14(17) fluoromethamphetamine;
7.15(18) α-methylaminobutyrophenone (MABP or buphedrone);
7.16(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
7.17(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
7.18(21) naphthylpyrovalerone (naphyrone);
7.19(22) and any other substance, except bupropion or compounds listed under a
7.20different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
7.21at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
7.22the compound is further modified in any of the following ways:
7.23(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
7.24haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
7.25system by one or more other univalent substituents;
7.26(ii) by substitution at the 3-position with an acyclic alkyl substituent;
7.27(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
7.28methoxybenzyl groups; or
7.29(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
7.30(7) (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
7.31specifically excepted or unless listed in another schedule, any natural or synthetic material,
7.32compound, mixture, or preparation that contains any quantity of a substance that is a
7.33cannabinoid receptor agonist, including, but not limited to, the following substances and,
7.34their analogs, including isomers, whether optical, positional, or geometric; esters;, ethers;,
7.35salts;, and salts of isomers, esters, and ethers, whenever the existence of the isomers,
7.36esters, ethers, or salts is possible within the specific chemical designation:
8.11-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
8.2(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015),
8.31-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole
8.4(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073),
8.54-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081),
8.64-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone
8.7(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
8.8(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone
8.9(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203),
8.104-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210),
8.112-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250),
8.121-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)-
8.139-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
8.14tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3-
8.15(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
8.16(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497),
8.17dimethylheptylpyran.
8.18(1) marijuana;
8.19(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
8.20synthetic equivalents of the substances contained in the cannabis plant or in the
8.21resinous extractives of the plant, or synthetic substances with similar chemical structure
8.22and pharmacological activity to those substances contained in the plant or resinous
8.23extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
8.24tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
8.25(3) synthetic cannabinoids, including the following substances:
8.26(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
8.27structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
8.28alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
8.292-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
8.30extent and whether or not substituted in the naphthyl ring to any extent. Examples of
8.31naphthoylindoles include, but are not limited to:
8.32(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
8.33(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
8.34(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
8.35(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
8.36(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
9.1(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
9.2(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
9.3(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
9.4(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
9.5(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
9.6(ii) Napthylmethylindoles, which are any compounds containing a
9.71H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
9.8of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.91-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
9.10substituted in the indole ring to any extent and whether or not substituted in the naphthyl
9.11ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
9.12(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
9.13(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
9.14(iii) Naphthoylpyrroles, which are any compounds containing a
9.153-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
9.16pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.171-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
9.18further substituted in the pyrrole ring to any extent, whether or not substituted in the
9.19naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
9.20(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
9.21(iv) Naphthylmethylindenes, which are any compounds containing a
9.22naphthylideneindene structure with substitution at the 3-position of the indene
9.23ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.241-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
9.25substituted in the indene ring to any extent, whether or not substituted in the naphthyl
9.26ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
9.27E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
9.28(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
9.29structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9.30alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
9.312-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
9.32any extent, whether or not substituted in the phenyl ring to any extent. Examples of
9.33phenylacetylindoles include, but are not limited to:
9.34(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
9.35(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
9.36(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
10.1(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
10.2(vi) Cyclohexylphenols, which are compounds containing a
10.32-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
10.4of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
10.51-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
10.6substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
10.7but are not limited to:
10.8(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
10.9(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
10.10(Cannabicyclohexanol or CP 47,497 C8 homologue);
10.11(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
10.12-phenol (CP 55,940).
10.13(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
10.14structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
10.15alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
10.162-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
10.17any extent and whether or not substituted in the phenyl ring to any extent. Examples of
10.18benzoylindoles include, but are not limited to:
10.19(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
10.20(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
10.21(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
10.22(WIN 48,098 or Pravadoline).
10.23(viii) Others specifically named:
10.24(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.25-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
10.26(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.27-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
10.28(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
10.29-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).
10.30(8) (i) A controlled substance analog, to the extent that it is implicitly or explicitly
10.31intended for human consumption.
10.32    Subd. 3. Schedule II. The following items are listed in (a) Schedule II: consists of
10.33the substances listed in this subdivision.
10.34(1) (b) Unless specifically excepted or unless listed in another schedule, any of
10.35the following substances whether produced directly or indirectly by extraction from
11.1substances of vegetable origin or independently by means of chemical synthesis, or by a
11.2combination of extraction and chemical synthesis:
11.3(a) (1) Opium and opiate, and any salt, compound, derivative, or preparation
11.4of opium or opiate, including the following: raw opium, opium extracts, opium
11.5fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine,
11.6codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone,
11.7oxymorphone, thebaine.
11.8(i) Excluding:
11.9(A) apomorphine;
11.10(B) thebaine-derived butorphanol;
11.11(C) dextrophan;
11.12(D) nalbuphine;
11.13(E) nalmefene;
11.14(F) naloxone;
11.15(G) naltrexone;
11.16(H) and their respective salts;
11.17(ii) but including the following:
11.18(A) opium, in all forms and extracts;
11.19(B) codeine;
11.20(C) dihydroetorphine;
11.21(D) ethylmorphine;
11.22(E) etorphine hydrochloride;
11.23(F) hydrocodone;
11.24(G) hydromorphone;
11.25(H) metopon;
11.26(I) morphine;
11.27(J) oxycodone;
11.28(K) oxymorphone;
11.29(L) thebaine;
11.30(M) oripavine;
11.31(b) (2) any salt, compound, derivative, or preparation thereof which is chemically
11.32equivalent or identical with any of the substances referred to in clause (a) (1), except that
11.33these substances shall not include the isoquinoline alkaloids of opium.;
11.34(c) (3) opium poppy and poppy straw.;
11.35(d) (4) coca leaves and any salt, cocaine compound, derivative, or preparation
11.36of coca leaves, including cocaine and ecgonine, the salts and isomers of cocaine and
12.1ecgonine, and the salts of their isomers. (including cocaine and ecgonine and their salts,
12.2isomers, derivatives, and salts of isomers and derivatives), and any salt, compound,
12.3derivative, or preparation thereof which is chemically equivalent or identical with any of
12.4these substances, except that the substances shall not include decocainized coca leaves or
12.5extraction of coca leaves, which extractions do not contain cocaine or ecgonine;
12.6(e) Any salt, compound, derivative, or preparation thereof which is chemically
12.7equivalent or identical with any of the substances referred to in clause (d), except that
12.8the substances shall not include decocainized coca leaves or extraction of coca leaves,
12.9which extractions do not contain cocaine or ecgonine. (5) concentrate of poppy straw (the
12.10crude extract of poppy straw in either liquid, solid, or powder form which contains the
12.11phenanthrene alkaloids of the opium poppy).
12.12(2) (c) Any of the following opiates, including their isomers, esters, ethers, salts, and
12.13salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
12.14schedule, whenever the existence of such isomers, esters, ethers and salts is possible
12.15within the specific chemical designation:
12.16(1) alfentanil;
12.17(2) alphaprodine;
12.18(3) anileridine;
12.19(4) bezitramide;
12.20(5) bulk dextropropoxyphene (nondosage forms);
12.21(6) carfentanil;
12.22(7) dihydrocodeine;
12.23(8) dihydromorphinone;
12.24(9) diphenoxylate;
12.25(10) fentanyl;
12.26(11) isomethadone;
12.27(12) levo-alpha-acetylmethadol (LAAM) levomethorphan;
12.28(13) levorphanol;
12.29(14) metazocine;
12.30(15) methadone;
12.31(16) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
12.32(17) moramide - intermediate, 2-methyl-3-morpholino-1,
12.331-diphenyl-propane-carboxylic acid;
12.34(18) pethidine;
12.35(19) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
12.36(20) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
13.1(21) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
13.2(22) phenazocine;
13.3(23) piminodine;
13.4(24) racemethorphan;
13.5(25) racemorphan;
13.6(26) remifentanil;
13.7(27) sufentanil;
13.8(28) tapentadol.
13.9(3) (d) Unless specifically excepted or unless listed in another schedule, any
13.10material, compound, mixture, or preparation which contains any quantity of the following
13.11substances having a stimulant effect on the central nervous system:
13.12(a) (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
13.13(b) (2) methamphetamine, its salts, isomers, and salts of its isomers;
13.14(c) (3) phenmetrazine and its salts;
13.15(d) (4) methylphenidate;
13.16(5) lisdexamfetamine.
13.17(4) (e) Unless specifically excepted or unless listed in another schedule, any
13.18material, compound, mixture, or preparation which contains any quantity of the following
13.19substances having a depressant effect on the central nervous system, including its salts,
13.20isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
13.21isomers is possible within the specific chemical designation:
13.22(a) methaqualone
13.23(b) (1) amobarbital;
13.24(2) glutethimide;
13.25(c) (3) secobarbital;
13.26(d) (4) pentobarbital;
13.27(e) (5) phencyclidine;
13.28(f) (6) phencyclidine immediate precursors:
13.29(i) 1-phenylcyclohexylamine;
13.30(ii) 1-piperidinocyclohexanecarbonitrile;
13.31(7) phenylacetone.
13.32(f) Hallucinogenic substances: nabilone.
13.33    Subd. 4. Schedule III. The following items are listed in (a) Schedule III: consists of
13.34the substances listed in this subdivision.
13.35(1) Any material, compound, mixture, or preparation which contains any quantity of
13.36Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine
14.1and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate;
14.2and which is required by federal law to be labeled with the symbol prescribed by 21 Code
14.3of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that
14.4the drug is listed as a Schedule III controlled substance under federal law. (b) Stimulants.
14.5Unless specifically excepted or unless listed in another schedule, any material, compound,
14.6mixture, or preparation which contains any quantity of the following substances having
14.7a potential for abuse associated with a stimulant effect on the central nervous system,
14.8including its salts, isomers, and salts of such isomers whenever the existence of such salts,
14.9isomers, and salts of isomers is possible within the specific chemical designation:
14.10(1) benzphetamine;
14.11(2) chlorphentermine;
14.12(3) clortermine;
14.13(4) phendimetrazine.
14.14(2) (c) Depressants. Unless specifically excepted or unless listed in another schedule,
14.15any material, compound, mixture, or preparation which contains any quantity of the
14.16following substances having a potential for abuse associated with a depressant effect on
14.17the central nervous system:
14.18(a) (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
14.19pentobarbital or any salt thereof and one or more other active medicinal ingredients which
14.20are not listed in any schedule.;
14.21(b) (2) any suppository dosage form containing amobarbital, secobarbital,
14.22pentobarbital, or any salt of any of these drugs and approved by the food and drug
14.23administration for marketing only as a suppository.;
14.24(c) (3) any substance which contains any quantity of a derivative of barbituric acid,
14.25or any salt of a derivative of barbituric acid, except those substances which are specifically
14.26listed in other schedules: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide;
14.27Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.;
14.28(d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of
14.29gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers,
14.30esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers,
14.31esters, and salts is possible within the specific chemical designation. (4) any drug product
14.32containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers,
14.33for which an application is approved under section 505 of the federal Food, Drug, and
14.34Cosmetic Act;
14.35(5) any of the following substances:
14.36(i) chlorhexadol;
15.1(ii) ketamine, its salts, isomers and salts of isomers;
15.2(iii) lysergic acid;
15.3(iv) lysergic acid amide;
15.4(v) methyprylon;
15.5(vi) sulfondiethylmethane;
15.6(vii) sulfonenthylmethane;
15.7(viii) sulfonmethane;
15.8(ix) tiletamine and zolazepam and any salt thereof;
15.9(x) embutramide.
15.10(3) Any material, compound, mixture, or preparation which contains any quantity of
15.11the following substances having a potential for abuse associated with a stimulant effect on
15.12the central nervous system:
15.13(a) Benzphetamine
15.14(b) Chlorphentermine
15.15(c) Clortermine
15.16(d) Mazindol
15.17(e) Phendimetrazine.
15.18(4) (d) Nalorphine.
15.19(5) Any material, compound, mixture, or preparation containing limited quantities
15.20of any of the following narcotic drugs, or any salts thereof (e) Narcotic drugs. Unless
15.21specifically excepted or unless listed in another schedule, any material, compound,
15.22mixture, or preparation containing any of the following narcotic drugs, or their salts
15.23calculated as the free anhydrous base or alkaloid, in limited quantities as follows:
15.24(a) (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
15.25milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
15.26of opium.;
15.27(b) (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
15.28milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
15.29therapeutic amounts.;
15.30(c) (3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or
15.31not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an
15.32isoquinoline alkaloid of opium.;
15.33(d) (4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
15.34more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
15.35in recognized therapeutic amounts.;
16.1(e) (5) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more
16.2than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
16.3recognized therapeutic amounts.;
16.4(f) (6) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
16.5than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
16.6recognized therapeutic amounts.;
16.7(g) (7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
16.8or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic
16.9ingredients in recognized therapeutic amounts.;
16.10(h) (8) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
16.11with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.;
16.12(6) (f) Anabolic steroids, which and human growth hormone.
16.13(1) Anabolic steroids, for purposes of this subdivision, means any drug or
16.14hormonal substance, chemically and pharmacologically related to testosterone, other
16.15than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes:
16.16androstanediol; androstanedione; androstenediol; androstenedione; bolasterone;
16.17boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol;
16.18dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone;
16.19drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human
16.20growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone;
16.214-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone;
16.22methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b,
16.2317b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane;
16.2417a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone;
16.25methyldienolone; methyltrienolone; methyltestosterone; mibolerone;
16.2617a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate;
16.27norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone;
16.28normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol;
16.29stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone;
16.30trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.
16.31(i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
16.32(ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
16.33(iii) androstanedione (5[alpha]-androstan-3,17-dione);
16.34(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;
16.35(v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
16.36(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
17.1(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
17.2(viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
17.3(ix) 4-androstenedione (androst-4-en-3,17-dione);
17.4(x) 5-androstenedione (androst-5-en-3,17-dione);
17.5(xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
17.6(xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
17.7(xiii) boldione (androsta-1,4-diene-3,17-dione);
17.8(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
17.9(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);
17.10(xvi) dehydrochloromethyltestosterone
17.11(4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);
17.12(xvii) desoxymethyltestosterone
17.13(17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
17.14(xviii) [delta]1-dihydrotestosterone-
17.15(17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.16(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
17.17(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
17.18(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
17.19(xxii) fluoxymesterone
17.20(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
17.21(xxiii) formebolone
17.22(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
17.23(xxiv) furazabol
17.24(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
17.25-hydroxygon-4-en-3-one;
17.26(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
17.27(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
17.28(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.29(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.30(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
17.31(xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
17.32(xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.33(xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
17.34(xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
17.35(xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
18.1(xxxv) 17[alpha]-methyl-4-hydroxynandrolone
18.2(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
18.3(xxxvi) methyldienolone
18.4(17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
18.5(xxxvii) methyltrienolone
18.6(17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
18.7(xxxviii) methyltestosterone
18.8(17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
18.9(xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
18.10(xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone
18.11(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
18.12(xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
18.13(xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
18.14(xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
18.15(3[beta],17[beta]-dihydroxyestr-5-ene;
18.16(xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
18.17(xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
18.18(xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
18.19(xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
18.20(xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
18.21(xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
18.22(l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
18.23(li) oxandrolone
18.24(17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
18.25(lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
18.26(liii) oxymetholone
18.27(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
18.28(liv) stanozolol
18.29(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
18.30(lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
18.31(lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
18.32lactone);
18.33(lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
18.34(lviii) tetrahydrogestrinone
18.35(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
18.36(lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
19.1(lx) any salt, ester, or ether of a drug or substance described in this paragraph.
19.2Anabolic steroids are not included if they are: (i) (A) expressly intended for administration
19.3through implants to cattle or other nonhuman species; and (ii) (B) approved by the United
19.4States Food and Drug Administration for that use.;
19.5(2) Human growth hormones.
19.6(g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and
19.7encapsulated in a soft gelatin capsule in a United States Food and Drug Administration
19.8approved product.
19.9(h) Any material, compound, mixture, or preparation containing the following
19.10narcotic drug or its salt: buprenorphine.
19.11    Subd. 5. Schedule IV. The following items are listed in Schedule IV: Barbital;
19.12Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam;
19.13Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine;
19.14Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with
19.15the following drugs in the following or lower concentrations: conjugated estrogens, 0.4
19.16mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital;
19.17Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine (a)
19.18Schedule IV consists of the substances listed in this subdivision.
19.19(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
19.20any material, compound, mixture, or preparation containing any of the following narcotic
19.21drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
19.22as follows:
19.23(1) not more than one milligram of difenoxin and not less than 25 micrograms of
19.24atropine sulfate per dosage unit;
19.25(2) dextropropoxyphene (Darvon and Darvocet).
19.26(c) Depressants. Unless specifically excepted or unless listed in another schedule,
19.27any material, compound, mixture, or preparation containing any quantity of the following
19.28substances, including its salts, isomers, and salts of isomers whenever the existence of the
19.29salts, isomers, and salts of isomers is possible:
19.30(1) alprazolam;
19.31(2) barbital;
19.32(3) bromazepam;
19.33(4) camazepam;
19.34(5) carisoprodol;
19.35(6) chloral betaine;
19.36(7) chloral hydrate;
20.1(8) chlordiazepoxide;
20.2(9) clobazam;
20.3(10) clonazepam;
20.4(11) clorazepate;
20.5(12) clotiazepam;
20.6(13) cloxazolam;
20.7(14) delorazepam;
20.8(15) diazepam;
20.9(16) dichloralphenazone;
20.10(17) estazolam;
20.11(18) ethchlorvynol;
20.12(19) ethinamate;
20.13(20) ethyl loflazepate;
20.14(21) fludiazepam;
20.15(22) flurazepam;
20.16(23) halazepam;
20.17(24) haloxazolam;
20.18(25) ketazolam;
20.19(26) loprazolam;
20.20(27) lorazepam;
20.21(28) lormetazepam mebutamate;
20.22(29) medazepam;
20.23(30) meprobamate;
20.24(31) methohexital;
20.25(32) methylphenobarbital;
20.26(33) midazolam;
20.27(34) nimetazepam;
20.28(35) nitrazepamnordiazepam;
20.29(36) oxazepam;
20.30(37) oxazolam;
20.31(38) paraldehydepetrichloral;
20.32(39) phenobarbital;
20.33(40) pinazepam;
20.34(41) prazepam;
20.35(42) quazepam;
20.36(43) temazepam;
21.1(44) tetrazepam;
21.2(45) triazolam;
21.3(46) zaleplon;
21.4(47) zolpidem;
21.5(48) zopiclone.
21.6(d) Any material, compound, mixture, or preparation which contains any quantity of
21.7the following substance including its salts, isomers, and salts of such isomers, whenever
21.8the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
21.9(e) Stimulants. Unless specifically excepted or unless listed in another schedule,
21.10any material, compound, mixture, or preparation which contains any quantity of the
21.11following substances having a stimulant effect on the central nervous system, including its
21.12salts, isomers, and salts of isomers:
21.13(1) cathine (norpseudoephedrine);
21.14(2) diethylpropion;
21.15(3) fencamfamine;
21.16(4) fenproporex;
21.17(5) mazindol;
21.18(6) mefenorex;
21.19(7) modafinil;
21.20(8) pemoline (including organometallic complexes and chelates thereof);
21.21(9) phentermine;
21.22(10) pipradol;
21.23(11) sibutramine;
21.24(12) SPA (1-dimethylamino-1,2-diphenylethane).
21.25    Subd. 6. Schedule V; restrictions on methamphetamine precursor drugs. (a) As
21.26used in this subdivision, the following terms have the meanings given:
21.27(1) "methamphetamine precursor drug" means any compound, mixture, or
21.28preparation intended for human consumption containing ephedrine or pseudoephedrine as
21.29its sole active ingredient or as one of its active ingredients; and
21.30(2) "over-the-counter sale" means a retail sale of a drug or product but does not
21.31include the sale of a drug or product pursuant to the terms of a valid prescription.
21.32(b) The following items are listed in Schedule V:
21.33(1) any compound, mixture, or preparation containing any of the following limited
21.34quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
21.35ingredients in sufficient proportion to confer upon the compound, mixture or preparation
21.36valuable medicinal qualities other than those possessed by the narcotic drug alone:
22.1(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
22.2grams;
22.3(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
22.4grams;
22.5(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
22.6of atropine sulfate per dosage unit; or
22.7(iv) not more than 15 milligrams of anhydrous morphine per 100 milliliters or per
22.8100 grams; and 100 milligrams of opium per 100 milliliters or per 100 grams; or
22.9(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
22.10atropine sulfate per dosage unit.
22.11(2) Stimulants. Unless specifically exempted or excluded or unless listed in another
22.12schedule, any material, compound, mixture, or preparation that contains any quantity of
22.13the following substance having a stimulant effect on the central nervous system, including
22.14its salts, isomers, and salts of isomers: pyrovalerone.
22.15(3) Depressants. Unless specifically exempted or excluded or unless listed in another
22.16schedule, any material, compound, mixture, or preparation that contains any quantity
22.17of the following substance having a depressant effect on the central nervous system,
22.18including its salts, isomers, and salts of isomers:
22.19(i) pregabalin;
22.20(ii) lacosamide.
22.21(2) (4) Any compound, mixture, or preparation containing ephedrine or
22.22pseudoephedrine as its sole active ingredient or as one of its active ingredients.
22.23(c) No person may sell in a single over-the-counter sale more than two packages
22.24of a methamphetamine precursor drug or a combination of methamphetamine precursor
22.25drugs or any combination of packages exceeding a total weight of six grams, calculated as
22.26the base.
22.27(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:
22.28(1) packages containing not more than a total of three grams of one or
22.29more methamphetamine precursor drugs, calculated in terms of ephedrine base or
22.30pseudoephedrine base; or
22.31(2) for nonliquid products, sales in blister packs, where each blister contains not
22.32more than two dosage units, or, if the use of blister packs is not technically feasible, sales
22.33in unit dose packets or pouches.
22.34(e) A business establishment that offers for sale methamphetamine precursor drugs
22.35in an over-the-counter sale shall ensure that all packages of the drugs are displayed
22.36behind a checkout counter where the public is not permitted and are offered for sale only
23.1by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
23.2establishment shall ensure that the person making the sale requires the buyer:
23.3(1) to provide photographic identification showing the buyer's date of birth; and
23.4(2) to sign a written or electronic document detailing the date of the sale, the name
23.5of the buyer, and the amount of the drug sold.
23.6A document described under clause (2) must be retained by the establishment for
23.7at least three years and must at all reasonable times be open to the inspection of any
23.8law enforcement agency.
23.9Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
23.10purchase.
23.11(f) No person may acquire through over-the-counter sales more than six grams of
23.12methamphetamine precursor drugs, calculated as the base, within a 30-day period.
23.13(g) No person may sell in an over-the-counter sale a methamphetamine precursor
23.14drug to a person under the age of 18 years. It is an affirmative defense to a charge under
23.15this paragraph if the defendant proves by a preponderance of the evidence that the
23.16defendant reasonably and in good faith relied on proof of age as described in section
23.17340A.503, subdivision 6 .
23.18(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
23.19a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
23.20payment of a fine of not more than $1,000, or both.
23.21(i) An owner, operator, supervisor, or manager of a business establishment that
23.22offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
23.23or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
23.24penalties for violating any of those paragraphs if the person:
23.25(1) did not have prior knowledge of, participate in, or direct the employee or agent to
23.26commit the violation; and
23.27(2) documents that an employee training program was in place to provide the
23.28employee or agent with information on the state and federal laws and regulations regarding
23.29methamphetamine precursor drugs.
23.30(j) Any person employed by a business establishment that offers for sale
23.31methamphetamine precursor drugs who sells such a drug to any person in a suspicious
23.32transaction shall report the transaction to the owner, supervisor, or manager of the
23.33establishment. The owner, supervisor, or manager may report the transaction to local law
23.34enforcement. A person who reports information under this subdivision in good faith is
23.35immune from civil liability relating to the report.
23.36(k) Paragraphs (b) to (j) do not apply to:
24.1(1) pediatric products labeled pursuant to federal regulation primarily intended for
24.2administration to children under 12 years of age according to label instructions;
24.3(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
24.4being manufactured in a manner that prevents the drug from being used to manufacture
24.5methamphetamine;
24.6(3) methamphetamine precursor drugs in gel capsule or liquid form; or
24.7(4) compounds, mixtures, or preparations in powder form where pseudoephedrine
24.8constitutes less than one percent of its total weight and is not its sole active ingredient.
24.9(l) The Board of Pharmacy, in consultation with the Department of Public Safety,
24.10shall certify methamphetamine precursor drugs that meet the requirements of paragraph
24.11(k), clause (2), and publish an annual listing of these drugs.
24.12(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
24.13pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
24.14States Drug Enforcement Administration are exempt from the methamphetamine precursor
24.15drug storage requirements of this section.
24.16(n) This section preempts all local ordinances or regulations governing the sale
24.17by a business establishment of over-the-counter products containing ephedrine or
24.18pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.
24.19    Subd. 7. Board of Pharmacy; regulation of substances. The Board of Pharmacy
24.20is authorized to regulate and define additional substances which contain quantities of a
24.21substance possessing abuse potential in accordance with the following criteria:
24.22(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the
24.23substance has: A high potential for abuse, no currently accepted medical use in the United
24.24States, and a lack of accepted safety for use under medical supervision.
24.25(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the
24.26substance has: A high potential for abuse, currently accepted medical use in the United
24.27States, or currently accepted medical use with severe restrictions, and that abuse may lead
24.28to severe psychological or physical dependence.
24.29(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the
24.30substance has: A potential for abuse less than the substances listed in Schedules I and II,
24.31currently accepted medical use in treatment in the United States, and that abuse may lead
24.32to moderate or low physical dependence or high psychological dependence.
24.33(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that
24.34the substance has: A low potential for abuse relative to the substances in Schedule III,
24.35currently accepted medical use in treatment in the United States, and that abuse may lead
25.1to limited physical dependence or psychological dependence relative to the substances in
25.2Schedule III.
25.3(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the
25.4substance has: A low potential for abuse relative to the substances listed in Schedule IV,
25.5currently accepted medical use in treatment in the United States, and limited physical
25.6dependence and/or psychological dependence liability relative to the substances listed
25.7in Schedule IV.
25.8    Subd. 8. Add, delete, or reschedule substances. The state Board of Pharmacy may,
25.9by rule, add substances to or delete or reschedule substances listed in this section. The
25.10Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as
25.11provided in subdivision 12.
25.12In making a determination regarding a substance, the Board of Pharmacy shall
25.13consider the following: The actual or relative potential for abuse, the scientific evidence
25.14of its pharmacological effect, if known, the state of current scientific knowledge
25.15regarding the substance, the history and current pattern of abuse, the scope, duration,
25.16and significance of abuse, the risk to public health, the potential of the substance to
25.17produce psychic or physiological dependence liability, and whether the substance is an
25.18immediate precursor of a substance already controlled under this section. The state Board
25.19of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal
25.20use in a schedule only if such drug must, under either federal or state law or rule, be
25.21sold only on prescription.
25.22    Subd. 8a. Methamphetamine precursors. The State Board of Pharmacy may,
25.23by order, require that nonprescription ephedrine or pseudophedrine products sold in
25.24gel capsule or liquid form be subject to the sale restrictions established in subdivision
25.256 for methamphetamine precursor drugs, if the board concludes that ephedrine or
25.26pseudophedrine products in gel capsule or liquid form can be used to manufacture
25.27methamphetamine. In assessing the need for an order under this subdivision, the board
25.28shall consult at least annually with the advisory council on controlled substances, the
25.29commissioner of public safety, and the commissioner of health.
25.30    Subd. 8b. Board of Pharmacy; expedited scheduling of additional substances.
25.31(a) The state Board of Pharmacy may, by rule, add a substance to Schedule I provided that
25.32it finds that the substance has a high potential for abuse, has no currently accepted medical
25.33use in the United States, has a lack of accepted safety for use under medical supervision,
25.34has known adverse health effects, and is currently available for use within the state. For
25.35the purposes of this subdivision only, the board may use the expedited rulemaking process
25.36under section 14.389. The scheduling of a substance under this subdivision expires the
26.1day after the adjournment of the legislative session immediately following the substance's
26.2scheduling unless the legislature by law ratifies the action.
26.3(b) If the board schedules a substance under this subdivision, the board shall notify
26.4in a timely manner the chairs and ranking minority members of the senate and house of
26.5representatives committees having jurisdiction over criminal justice and health policy
26.6and finance of the action and the reasons for it. The notice must include a copy of the
26.7administrative law judge's decision on the matter.
26.8(c) This subdivision expires August 1, 2014.
26.9    Subd. 9. Except substances by rule. The state Board of Pharmacy may by rule
26.10except any compound, mixture, or preparation containing any stimulant or depressant
26.11substance listed in subdivision 4, clauses (1) and (2) paragraphs (b) and (c), or in
26.12subdivisions 5 and 6 from the application of all or any part of this chapter, if the
26.13compound, mixture, or preparation contains one or more active medicinal ingredients not
26.14having a stimulant or depressant effect on the central nervous system; provided, that
26.15such admixtures shall be included therein in such combinations, quantity, proportion,
26.16or concentration as to vitiate the potential for abuse of the substances which do have a
26.17stimulant or depressant effect on the central nervous system.
26.18    Subd. 10. Dextromethorphan. Dextromethorphan shall not be deemed to be
26.19included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless
26.20controlled pursuant to the foregoing provisions of this section.
26.21    Subd. 12. Coordination of controlled substance regulation with federal law and
26.22state statute. If any substance is designated, rescheduled, or deleted as a controlled
26.23substance under federal law and notice thereof is given to the state Board of Pharmacy, the
26.24state Board of Pharmacy shall similarly control the substance under this chapter, after the
26.25expiration of 30 days from publication in the Federal Register of a final order designating
26.26a substance as a controlled substance or rescheduling or deleting a substance. Such order
26.27shall be filed with the secretary of state. If within that 30-day period, the state Board of
26.28Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for
26.29objection and afford all interested parties an opportunity to be heard. At the conclusion of
26.30the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject
26.31to the provisions of chapter 14.
26.32In exercising the authority granted by this chapter, the state Board of Pharmacy shall
26.33be subject to the provisions of chapter 14. The state Board of Pharmacy shall provide
26.34copies of any proposed rule under this chapter to the advisory council on controlled
26.35substances at least 30 days prior to any hearing required by section 14.14, subdivision 1.
27.1The state Board of Pharmacy shall consider the recommendations of the advisory council
27.2on controlled substances, which may be made prior to or at the hearing.
27.3The state Board of Pharmacy shall annually submit a report to the legislature on or
27.4before December 1 that specifies what changes the board made to the controlled substance
27.5schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in
27.6the preceding 12 months. The report must include specific recommendations for amending
27.7the controlled substance schedules contained in subdivisions 2 to 6, so that they conform
27.8with the controlled substance schedules maintained by the board in Minnesota Rules,
27.9parts 6800.4210 to 6800.4250.
27.10    Subd. 13. Implementation study. Annually, the state Board of Pharmacy shall study
27.11the implementation of this chapter in relation to the problems of drug abuse in Minnesota.
27.12EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
27.13committed on or after that date.

27.14    Sec. 2. Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is
27.15amended to read:
27.16    Subd. 6. Sale or possession of synthetic cannabinoids. (a) As used in this
27.17subdivision, "synthetic cannabinoid" includes any substance included in section 152.02,
27.18subdivision 2, paragraph (h), clause (7) (3).
27.19(b) A person who unlawfully sells a synthetic cannabinoid for no remuneration is
27.20guilty of a gross misdemeanor.
27.21(c) A person who unlawfully sells any amount of a synthetic cannabinoid is guilty of
27.22a gross misdemeanor felony and if convicted may be sentenced to imprisonment for not
27.23more than five years or to payment of a fine of not more than $10,000, or both.
27.24(c) (d) A person who unlawfully possesses any amount of a synthetic cannabinoid is
27.25guilty of a misdemeanor.
27.26(d) (e) Notwithstanding any contrary provision in sections 152.021 to 152.025, this
27.27subdivision describes the exclusive penalties for the sale and possession of synthetic
27.28cannabinoid.
27.29EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
27.30committed on or after that date.

27.31    Sec. 3. Minnesota Statutes 2010, section 152.18, subdivision 1, is amended to read:
27.32    Subdivision 1. Deferring prosecution for certain first time drug offenders. If
27.33any person who has not previously participated in or completed a diversion program
28.1authorized under section 401.065 or who has not previously been placed on probation
28.2without a judgment of guilty and thereafter been discharged from probation under
28.3this section is found guilty of a violation of section 152.024, subdivision 2, 152.025,
28.4subdivision 2 , or 152.027, subdivision 2, 3, or 4, or 6, paragraph (d), for possession of a
28.5controlled substance, after trial or upon a plea of guilty, and the court determines that the
28.6violation does not qualify as a subsequent controlled substance conviction under section
28.7152.01, subdivision 16a , the court may, without entering a judgment of guilty and with the
28.8consent of the person, defer further proceedings and place the person on probation upon
28.9such reasonable conditions as it may require and for a period, not to exceed the maximum
28.10sentence provided for the violation. The court may give the person the opportunity to
28.11attend and participate in an appropriate program of education regarding the nature and
28.12effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a
28.13condition of the probation, the court may enter an adjudication of guilt and proceed as
28.14otherwise provided. The court may, in its discretion, dismiss the proceedings against the
28.15person and discharge the person from probation before the expiration of the maximum
28.16period prescribed for the person's probation. If during the period of probation the person
28.17does not violate any of the conditions of the probation, then upon expiration of the period
28.18the court shall discharge the person and dismiss the proceedings against that person.
28.19Discharge and dismissal under this subdivision shall be without court adjudication of guilt,
28.20but a not public record of it shall be retained by the Bureau of Criminal Apprehension
28.21for the purpose of use by the courts in determining the merits of subsequent proceedings
28.22against the person. The not public record may also be opened only upon court order for
28.23purposes of a criminal investigation, prosecution, or sentencing. Upon request by law
28.24enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting
28.25party of the existence of the not public record and the right to seek a court order to open it
28.26pursuant to this section. The court shall forward a record of any discharge and dismissal
28.27under this subdivision to the bureau which shall make and maintain the not public record
28.28of it as provided under this subdivision. The discharge or dismissal shall not be deemed a
28.29conviction for purposes of disqualifications or disabilities imposed by law upon conviction
28.30of a crime or for any other purpose.
28.31For purposes of this subdivision, "not public" has the meaning given in section
28.3213.02, subdivision 8a .
28.33EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
28.34committed on or after that date."
28.35Delete the title and insert:

28.36"A bill for an act

29.1relating to public safety; aligning state-controlled substance schedules with
29.2federal controlled substance schedules; modifying the authority of the Board of
29.3Pharmacy to regulate controlled substances; providing for penalties;amending
29.4Minnesota Statutes 2010, sections 152.02, as amended; 152.18, subdivision 1;
29.5Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6."

30.1	We request the adoption of this report and repassage of the bill.
30.2	House Conferees:
30.3	.....		.....
30.4	Bob Barrett		John Kriesel
30.5	.....
30.6	Kerry Gauthier
30.7	Senate Conferees:
30.8	.....		.....
30.9	Scott J. Newman		Bill G. Ingebrigtsen
30.10	.....
30.11	Roger J. Reinert